Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INDP Stock Forecast 2025-2026
$0.40
Current Price
$6.42M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INDP Price Targets
+398.8%
To High Target of $2.00
+398.8%
To Median Target of $2.00
+398.8%
To Low Target of $2.00
INDP Price Momentum
-13.0%
1 Week Change
-16.7%
1 Month Change
-81.4%
1 Year Change
-52.4%
Year-to-Date Change
-87.1%
From 52W High of $3.10
+0.2%
From 52W Low of $0.40
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Indaptus Therapeutics (INDP) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on INDP and similar high-potential opportunities.
Latest INDP Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, INDP has a bullish consensus with a median price target of $2.00 (ranging from $2.00 to $2.00). Currently trading at $0.40, the median forecast implies a 398.8% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INDP Analyst Ratings
1
Buy
0
Hold
0
Sell
INDP Price Target Range
Low
$2.00
Average
$2.00
High
$2.00
Current: $0.40
Latest INDP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INDP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $5.00 |
| Oct 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Jun 17, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Apr 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Sep 20, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| May 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Mar 20, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
| Mar 8, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Overweight | Reiterates | $15.00 |
| Feb 8, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Jan 31, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Assumes | $15.00 |
| Oct 19, 2021 | Maxim Group | Jason McCarthy | Buy | Upgrade | $16.00 |
Indaptus Therapeutics Inc. (INDP) Competitors
The following stocks are similar to Indaptus Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
INDP
Indaptus Therapeutics
mkt cap
6.15M
Indaptus Therapeutics Inc. (INDP) Financial Data
Indaptus Therapeutics Inc. has a market capitalization of $6.42M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -187.5%.
Valuation Metrics
Market Cap
$6.42M
Enterprise Value
$77,766
P/E Ratio
0.0x
PEG Ratio
-0.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+100.0%
Current Ratio
2.0x
Debt/Equity
2.1x
ROE
-187.5%
ROA
-86.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Indaptus Therapeutics Inc. (INDP) Business Model
About Indaptus Therapeutics Inc.
What They Do
Develops innovative immunotherapy treatments for diseases.
Business Model
Indaptus Therapeutics Inc. operates as a clinical-stage biopharmaceutical company that develops therapies targeting cancer, infectious diseases, and autoimmune disorders. The company generates revenue through the advancement of its drug candidates, which it aims to bring through clinical trials and ultimately to market, capitalizing on the growing demand for effective immunotherapies.
Additional Information
Focused on leveraging proprietary platform technologies in cytokine biology, Indaptus is positioned to enhance existing treatment options, potentially offering better efficacy and fewer side effects. Its commitment to innovation and scientific rigor places it at the forefront of the biotechnology sector, with the potential to significantly impact patient care and treatment paradigms.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Mr. Jeffrey A. Meckler J.D.
Country
United States
IPO Year
2021
Website
indaptusrx.comIndaptus Therapeutics Inc. (INDP) Latest News & Analysis
Latest News
Quick Summary
Indaptus Therapeutics' CSO, Dr. Michael Newman, will chair Day 2 of the Cytokine-Based Drug Development Summit in Boston on May 15-16, 2025.
Why It Matters
Michael Newman’s role at the summit highlights Indaptus's leadership in cytokine-based therapies, potentially boosting investor confidence in its innovation and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
1 month ago
Quick Summary
Indaptus Therapeutics' CMO, Roger Waltzman, will moderate a panel at the CMO360 Summit in Boston on April 7-8, 2025. The company focuses on therapies for cancer and viral infections.
Why It Matters
Indaptus Therapeutics' CMO moderating a key industry panel highlights the company's leadership and visibility, potentially boosting investor confidence and interest in its innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Indaptus Therapeutics (Nasdaq: INDP) has progressed to a new expansion phase in its Phase 1b/2 trial for Decoy20, testing it with BeiGene's tislelizumab for safety and efficacy.
Why It Matters
Indaptus Therapeutics advancing its clinical trial with Decoy20 and a PD-1 inhibitor signals potential breakthroughs in cancer treatment, impacting its stock value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Indaptus Therapeutics (Nasdaq: INDP) has enrolled over 20 patients in the weekly dosing cohort of its Phase 1 trial for Decoy20, marking a significant milestone in its clinical development.
Why It Matters
Positive trial updates and patient enrollment milestones can indicate potential breakthroughs, impacting stock performance and investor confidence in Indaptus Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Indaptus Therapeutics' CEO, Jeffrey Meckler, will present at a webinar on March 17, 2025, focused on immune system insights. Registration is available at Tribe Public's website.
Why It Matters
CEO presentations can influence investor sentiment and stock price, especially if new insights on immune therapies are shared. Market interest may rise, impacting trading volume and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported its financial results for Q4 and the fiscal year ending December 31, 2024, alongside a corporate update on March 13, 2025.
Why It Matters
Indaptus Therapeutics' quarterly and annual financial results can indicate its performance and growth potential, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About INDP Stock
What is Indaptus Therapeutics Inc.'s (INDP) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Indaptus Therapeutics Inc. (INDP) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $2.00.
Is INDP stock a good investment in 2025?
According to current analyst ratings, INDP has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INDP stock?
Wall Street analysts predict INDP stock could reach $2.00 in the next 12 months. This represents a 398.8% increase from the current price of $0.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Indaptus Therapeutics Inc.'s business model?
Indaptus Therapeutics Inc. operates as a clinical-stage biopharmaceutical company that develops therapies targeting cancer, infectious diseases, and autoimmune disorders. The company generates revenue through the advancement of its drug candidates, which it aims to bring through clinical trials and ultimately to market, capitalizing on the growing demand for effective immunotherapies.
What is the highest forecasted price for INDP Indaptus Therapeutics Inc.?
The highest price target for INDP is $2.00 from at , which represents a 398.8% increase from the current price of $0.40.
What is the lowest forecasted price for INDP Indaptus Therapeutics Inc.?
The lowest price target for INDP is $2.00 from at , which represents a 398.8% increase from the current price of $0.40.
What is the overall INDP consensus from analysts for Indaptus Therapeutics Inc.?
The overall analyst consensus for INDP is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are INDP stock price projections?
Stock price projections, including those for Indaptus Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 7:44 AM UTC